Fabrication and Characterization of Novel Liquid Film Forming Solution for Pain Management

The purpose of the current study’s is to develop, characterize, and analyze a novel transdermal film forming solution of Tramadol (TMD) in order to maximize drug availability, minimize the frequency of oral side effects, and eliminate the need for frequent dosing. Tramadol is an opiate pain reliever, used to treat moderate to severe pain caused on by both acute and chronic illnesses or injuries. They lessen pain by influencing your brain and nervous system. The preparation of Film Forming Solutions (FFS) for transdermal distribution of TMD involved the use of Eudragit-L100, HydroxyPropyl Methyl Cellulose (HPMC E5), and PVA as a film forming polymer, ethyl alcohol as a solvent, PEG 400 as a plasticizer. The pH, viscosity, drying time and drug content was assessed for FFS. They also underwent in-vitro drug release testing. For every test, every formulation produced results that fell within an acceptable range.The formulation F5 was determined to be the best based on the basis of physiochemical evaluation. Formulation gave 76.83% of sustained drug release within 10 hrs. It is further evaluated for SEM analysis and in vivo analgesic study. A film-forming solution formulation may be regarded as an acceptable approach for pain management because the developed formulation exhibited comparable analgesic activity to that of the commercially available traditional formulation.